In the news

Regardless of experience level, endoscopists reported successful use of the first single-use duodenoscope for endoscopic retrograde cholangiopancreatography, Adam Slivka, MD, PhD, University of Pittsburgh, told Healio Gastroenterology.

Boston Scientific today said it received CE mark approval for its Exalt Model B single-use bronchoscope. The company designed the device for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

Boston Scientific’s implant led to stroke rates 77% lower than typically expected among older people with atrial fibrillation and high risk scores.

Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other “highways” that his business group is addressing.

The clinical trial found a correlation between survival and radiation absorbed by the tumor, giving Boston Scientific data to make the case for using the recently approved device.

The FDA has approved TheraSphere™ Yttrium-90 (Y-90) Glass Microspheres for the treatment of patients with hepatocellular carcinoma.

Boston Scientific aims to acquire Lumenis’ global surgical laser business, through a $1.07 billion deal that will incorporate its systems for ear, nose and throat procedures and its Moses laser treatment for breaking apart kidney stones.

Boston Scientific is making moves to strengthen its line of rhythm management diagnostics with the acquisition of privately held Preventice Solutions, Inc., a company that not only offers remote monitoring for cardiac issues, but also integrates deep learning algorithms and artificial intelligence to generate data used in diagnosis.

Boston Scientific’s Vercise Genus deep brain stimulation (DBS) system portfolio is approved for conditional use in a magnetic resonance imaging (MRI) environment. It features a family of Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators capable of powering Cartesia directional leads to offer symptom relief for those suffering from Parkinson’s disease.

The systems are designed to deliver paresthesia-free pain relief in minutes. They are designed with Boston Scientific’s Fast-Acting Sub-perception Therapy (FAST) and have four MRI conditional, Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators.

In an effort to solve unemployment issues caused by the coronavirus pandemic and overcome language barriers in the growing Latino and Hispanic population in his community, an immigrant from Costa Rica helped launch an all Spanish-language work shift for Hispanic workers at a medical manufacturing company in Spencer.

Reusable duodenoscopes infected patients in a series of notorious outbreaks. Now there’s a disposable model to be used just once.

SVP Brad Sorenson gives context on how hospitals have recovered during the COVID-19 pandemic and are learning to bifurcate their business to handle both pandemic patients and more typical cases.

Boston Scientific has secured FDA approval for its Ranger paclitaxel-coated balloon, designed to help limit a patient’s systemic exposure to the chemotherapy used to slow the closure of reopened arteries.

“The CHAMPION-AF trial will compare the Watchman FLX device in a head-to-head fashion against best-in-class pharmacological therapy for stroke prevention and evaluate the technology as a first-line therapy for those who can tolerate anticoagulation,” said Ian Meredith, global chief medical officer, Boston Scientific.

How evolving treatment pathways are improving communication and care—both in person and remotely.

HR VP Camille Chang Gilmore explains why Boston Scientific is using data to shine light on healthcare inequality.

Boston Scientific has a plan to tackle systemic racism in healthcare, and to stop the "Black amputation epidemic."

Boston Scientific’s WaveWriter Alpha systems garnered CE Mark approval with indications for managing chronic intractable pain and peripheral nerve stimulation of the trunk for pain management.

This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original ACURATE neo platform.

Boston Scientific and IBM Research are working together to make chronic pain treatment more individualized—and effective.

“The motive is educating the community,” said Camille Chang Gilmore, global chief diversity officer at Boston Scientific. “We’ve been doing this for 16 years, and we’ve now evolved it to try and figure out how do we bring these resources to people.”

Vercise Genus, a fourth-generation system for deep brain stimulation (DBS), made by Boston Scientific, has received CE marketing and is now commercially available in Europe.

Tune in at the 33-minute mark to hear Boston Scientific’s Brian Dunkin, MD, CMO, Endoscopy, and Dave Pierce, EVP of MedSurg, discuss the EXALT™ Model D single-use duodenoscope in the DeviceTalks Weekly podcast.